Figure 6: In vivo anti-tumour properties of climacostol in mice bearing melanoma allografts. | Scientific Reports

Figure 6: In vivo anti-tumour properties of climacostol in mice bearing melanoma allografts.

From: Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme

Figure 6

When the B16-F10 syngeneic implantation was established animals were intra-tumour injected with vehicle (control) or climacostol at 600 μg/ml every 3–4 days for 3 weeks. (a) Typical photographs taken at different time-points and depicting the growth of subcutaneous melanomas, as indicated by red circles. (b) Tumour growth monitored by means of external caliper measurements and volume calculation. Arrows indicate the day of climacostol treatment. (c) Percentage survival analysed by Kaplan-Meier curve. Images and data points in (a–c) represent the results obtained from 7–15 animals per experimental group. (d) Typical photographs of subcutaneous melanoma allografts excised from mice at day 16 of treatment (from day 0 - every 3–4 days) with vehicle (control) or climacostol (600 μg/ml). Scale bar: 5 mm. (e) Weight of the excised tumours. Images and data in (d,e) represent the results obtained from 3 animals per experimental group. *p < 0.001 vs the respective control.

Back to article page